Posted by Michael Wonder on 27 Aug 2019
We need a more rational biosimilars policy
27 August 2019 - Throwing in the towel on a whole new category of medicines, just shy of a decade in, is not only shortsighted, it’s bad for patients and provider choice.
Peter B. Bach and Mark Trusheim say it’s “Time to Throw In the Towel on Biosimilars”, but throwing in the towel on a whole new category of medicines, just shy of a decade in, is shortsighted and bad for patients and provider choice.
Only with enactment of the Biologics Price Competition and Innovation Act of 2009 were biosimilars eligible for regulatory review. Since passage, we’ve seen 23 biosimilars approved by the Food and Drug Administration and continued development uptick from manufacturers.
